Opinion|Videos|January 3, 2025
Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection
Panelists discuss how in selecting first-line therapy for patients with newly diagnosed chronic myeloid leukemia, clinicians must carefully weigh factors including the patient’s risk score, comorbidities, drug interaction potential, monitoring requirements, and cost considerations while recognizing that available tyrosine kinase inhibitor options (imatinib, nilotinib, dasatinib, and bosutinib) have similar efficacy but distinct safety and tolerability profiles.
Advertisement
Video content above is prompted by the following:
- How do you choose between these therapies when assessing a patient newly diagnosed with chronic myeloid leukemia?
- Please comment on any similarities or differences in your clinical practice when selecting between the first-line therapy options.
Advertisement
Related to this article
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Sylvester cancer researchers became wildland firefighters themselves to study, from the inside, cancer risks tied to the job.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5